Abbott earnings off 44%

• Abbott (NYSE:ABT) Q3 results ($M): Total Revenues: 5,104 (+5.8%), Nutrition: 1,787 (+9.3%), Diagnostics: 1,180 (+4.9%), Established Pharmaceuticals: 771 (+11.5%), Medical Devices: 1,329 (-1.0%); COGS: 2,331 (+3.4%); R&D Expense: 307 (-9.4%); SG&A Expense: 1,603 (-0.6%); Net Income: 538 (-44.3%); EPS: 0.36 (-41.0%).
• Gross Profit: 2,773 (+7.9%); COGS: 45.7% (-2.3%); Gross Margin: 54.3% (+2.0%); Operating Profit: 863 (+39.4%); Operating Earnings Yield: 16.9% (+31.8%); Net Earnings Yield: 10.5% (-47.4%).
• 2014 Guidance: EPS: $1.22 - 1.24; non-GAAP EPS: $2.25 - 2.27 from $2.19 - 2.29.
• Q4 Guidance: EPS: $0.32 - 0.34; non-GAAP EPS: $0.68 - 0.70.